Literature DB >> 7545713

IL-13 down-regulates CD14 expression and TNF-alpha secretion in normal human monocytes.

G Cosentino1, E Soprana, C P Thienes, A G Siccardi, G Viale, D Vercelli.   

Abstract

CD14, a glycosylphosphatidylinositol (GPI)-linked protein expressed on monocytes and neutrophils, regulates monocyte-lymphocyte interactions and serves as the LPS receptor. We showed previously that IL-4 down-regulates the expression of human CD14 by acting at the transcriptional level. We now investigate whether CD14 expression could also be regulated by IL-13, another member of the chromosome 5 cytokine gene family. IL-13 dose-dependently inhibited CD14 expression on human monocytes. By contrast, expression of CD23 and CD11b was enhanced strongly. Down-regulation of CD14 involved neither shedding nor activation of endogenous GPI anchor-cleaving enzymes. Indeed, soluble CD14 was not increased in the supernatants of IL-13-stimulated monocytes, and expression of CD55/DAF, another GPI-linked protein, was unaffected by IL-13. CD14 transcript levels were reduced sixfold in IL-13-treated monocytes. These results suggest that IL-13 down-regulates membrane CD14 by suppressing CD14 RNA expression. IL-13-dependent down-regulation of CD14 resulted in the inhibition of CD14-mediated events. Indeed, CD14-mediated release of TNF-alpha was inhibited markedly (approximately 75%) in monocytes stimulated with LPS (100 ng/ml) after a 72-h preincubation with IL-13. However, IL-13 also directly inhibited monokine secretion, because it blocked PMA-induced, CD14-independent TNF-alpha release. Down-regulation of CD14 and TNF-alpha secretion may play a major role in the anti-inflammatory effects of IL-13 on LPS-stimulated monocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545713

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Increased levels of circulating soluble CD14 in Kawasaki disease.

Authors:  S Takeshita; K Nakatani; H Tsujimoto; Y Kawamura; H Kawase; I Sekine
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation.

Authors:  Frank D Vladich; Susan M Brazille; Debra Stern; Michael L Peck; Raffaella Ghittoni; Donata Vercelli
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Antisomnogenic cytokines, quality of life, and chronic rhinosinusitis: a pilot study.

Authors:  Jeremiah A Alt; Nathan B Sautter; Jess C Mace; Kara Y Detwiller; Timothy L Smith
Journal:  Laryngoscope       Date:  2013-10-22       Impact factor: 3.325

4.  Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation.

Authors:  M Goebeler; B Schnarr; A Toksoy; M Kunz; E B Bröcker; A Duschl; R Gillitzer
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

Review 5.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

6.  Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor-alpha production.

Authors:  S P Chen; W Cheung; C K Heng; S C Jordan; H K Yap
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 7.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

8.  Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan.

Authors:  M Heinzelmann; H C Polk; F N Miller
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Increased interleukin-13 expression in patients with sarcoidosis.

Authors:  H-P Hauber; D Gholami; A Meyer; A Pforte
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

10.  Treatment of uveitis with recombinant human interleukin-13.

Authors:  F G Roberge; M D de Smet; J Benichou; M F Kriete; J Raber; J Hakimi
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.